Eloxx Pharmaceuticals Announces First Two Patients Dosed In Phase 2b EXACT Study Of Exaluren In Nonsense Mutation Alport Syndrome; Topline Data Expected Mid-2027

Loading news article.

Eloxx Pharmaceuticals Announces First Two Patients Dosed In Phase 2b EXACT Study Of Exaluren In Nonsense Mutation Alport Syndrome; Topline Data Expected Mid-2027 | WAPE

Eloxx Pharmaceuticals Announces First Two Patients Dosed In Phase 2b EXACT Study Of Exaluren In Nonsense Mutation Alport Syndrome; Topline Data Expected Mid-2027

Article summary

Related companies

Comments —